Novan (NOVN +2.5%) perks up, albeit on light volume, following its announcement that its Phase 3 studies (B-SIMPLE 1&2) evaluating SB206 for the treatment of molluscum contagiosum are more than 50% enrolled.
Topline data should be available in Q1 2020.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.